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Neonatal rhesus macaque 95-3 was inoculated with nonpassaged simian-human immunodeficiency virus
strain SHIV-vpu, which encodes env of the laboratory-adapted human immunodeficiency virus (HIV) strain
IIIB and is considered nonpathogenic. CD4 T-cell counts dropped to <200 cells/l within 4.6 years, and
monkey 95-3 died with opportunistic infections 5.9 years postinoculation. Transfer of blood from 95-3 to two
naive adult macaques resulted in high peak viral loads and rapid, persistent T-cell depletion. Progeny virus
evolved in 95-3 despite high SHIV-vpu neutralizing antibody titers and still used CXCR4 but, in contrast to
parental SHIV-vpu, productively infected macrophages and resisted neutralization. Sequence analysis re-
vealed three new potential glycosylation sites in gp120; another two were lost. Strikingly similar mutations were
detected in a laboratory worker who progressed to AIDS after accidental HIV-IIIB infection (T. Beaumont et
al., J. Virol. 75:2246–2252, 2001), thus supporting the SHIV-vpu/rhesus macaque system as a relevant model.
Similar mutations were also described after rapid passage of chimeric viruses encoding IIIB env in rhesus and
pig-tailed macaques (M. Cayabyab et al., J. Virol. 73:976–984, 1999; Z. Q. Liu et al., Virology 260:295–307, 1999;
S. V. Narayan et al., Virology 256:54–63, 1999; R. Raghavan et al., Brain Pathol. 7:851–861, 1997; E. B. Stephens
et al., Virology 231:313–321, 1997). Thus, HIV-IIIB env evolved similarly in three different species; this selection
occurred in chronically infected individuals during disease progression as well as after rapid virus passage. We
postulate that evolutionary pressure led to the outgrowth of more aggressive viral variants in all three species.
Simian-human immunodeficiency viruses (SHIVs) contain
envelope and accessory genes of HIV type 1 (HIV-1) in a SIV
backbone (11, 16, 17, 26, 32, 33, 40). Several chimeric viruses
with different pathogenic potentials have been constructed.
Whereas some strains are highly pathogenic in rhesus ma-
caques (17, 24, 33, 34), others are thought to be nonpatho-
genic, such as SHIV-4 and SHIV-vpu (20, 21). The latter two
chimeras encode env of HXBc2, a molecular clone of the T-cell
line-adapted HIV-IIIB (20, 21). In contrast to SHIV-4, SHIV-
vpu contains an open vpu reading frame (20, 21). Both viruses
replicate in rhesus monkeys (2, 25, 36).
Rapid in vivo passage of viruses containing HIV-IIIB env
resulted in more aggressive variants that caused acute CD4
T-cell loss (15, 16, 31, 43). However, thus far, macaques inoc-
ulated with the nonpassaged viruses have not developed signs
of immune suppression or disease (20, 21). Here, we demon-
strate that nonpassaged SHIV-vpu can cause CD4 T-cell
depletion and AIDS after prolonged observation, thus approx-
imating the time course of untreated HIV-1 infections in hu-
mans.
Nonpassaged SHIV-vpu induces AIDS. After nontrau-
matic oral SHIV-vpu inoculation (10 oral 50% animal in-
fectious doses) (1), a neonatal rhesus monkey (Macaca mulatta
95-3) became systemically infected. Virus isolation from pe-
ripheral blood mononuclear cells (PBMC) (1, 22) was persis-
tently positive from weeks 2 to 49 postexposure and from week
228 onward. Viral RNA load in plasma measured by real-time
reverse transcription-PCR (RT-PCR) (13) continuously in-
creased from week 150 postexposure onward to reach 105
copies/ml (Fig. 1A). After seroconversion, anti-Gag antibodies
decreased again (Fig. 1B), a finding that heralds development
of immunodeficiency in SIV-infected monkeys and HIV-in-
fected humans (5). Interestingly, a transient rebound of the
anti-Gag antibodies was found at 123 weeks postexposure (Fig.
1B). CD4 T cells steadily declined after week 150 (Fig. 1C)
and were 50 cells/l during the last 7 months. The monkey
developed substantial weight loss and diarrhea and was sacri-
ficed at week 307. High viral burdens were detected by cocul-
tivation in lymphoid tissues (data not shown). Gross necropsy
and histology demonstrated lymphadenopathy, pneumocysto-
sis, and colitis with cryptitis. Infectious organisms found in this
animal are listed in Table 1.
Neutralizing activity against parental SHIV-vpu was ini-
tially low to moderate (Fig. 1D); the titers rose after viral RNA
loads had increased and before CD4 T-cell counts fell below
* Corresponding author: Mailing address: Dana-Farber Cancer In-
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632-3719. Fax: (617) 632-3112. E-mail: ruth_ruprecht@dfci.harvard
.edu.
5278
 o
n
 N
ovem
ber 30, 2016 by Universitaet Zuerich
http://jvi.asm.org/
D
ow
nloaded from
 
500 cells/l. Thus, progeny virus evolved in monkey 95-3 de-
spite high SHIV-vpu neutralizing antibody titers.
Parental SHIV-vpu evolved into a neutralization-resistant
and acutely pathogenic virus in animal 95-3. Virus isolated
from animal 95-3 at necropsy was highly resistant to neutral-
ization by plasma collected at weeks 180, 200, 225, 270, and 285
postinoculation (titers of 20), despite the presence of high
titers of antibodies that neutralized parental SHIV-vpu at all
time points (data not shown). Animal passage revealed that
monkey 95-3 harbored virus with markedly increased virulence
after it had progressed to AIDS. Blood (10 ml containing 642
infectious PBMC and 7.4  105 RNA copies) was collected at
week 291 postinoculation from monkey 95-3 and inoculated
intravenously into adult recipient monkey RJj-4. The animal
developed high virus loads, rapid CD4 T-cell losses in blood
(Fig. 2) and lymphoid tissue (data not shown), and refractory
diarrhea (Table 1). At week 43, RJj-4 had 24 CD4 T cells/l
and was euthanatized because of Pneumocystis carinii pneumo-
nia. A second blood transfer (10 ml containing 1.3  105
infectious PBMC and 1.26  108 RNA copies) from RJj-4 at
week 2 postexposure to animal RMk-4 also resulted in high
viral loads and rapid CD4 T-cell depletion (Fig. 2). RMk-4
was sacrificed at week 58 due to P. carinii pneumonia.
Unchanged CXCR4 usage but newly acquired ability to rep-
licate in macrophages. Acute pathogenicity was also observed
in pig-tailed macaques (Macaca nemestrina) after rapid pas-
sage of SHIVs encoding HIV-IIIB env (from HXBc2) (16, 43).
A molecular clone, SHIVKU-2MC4, isolated after further pas-
sage, caused acute CD4 T-cell loss and disease (23). Unlike
the parental SHIV-4, which is not macrophagetropic, these
progeny viruses replicated efficiently in macrophages (23, 44),
even though they continued to use CXCR4 as coreceptor (23).
We characterized coreceptor usage of viruses isolated from
FIG. 1. SHIV-vpuRNA load in plasma determined by real-time RT-PCR (A), anti-Gag antibodies (B), peripheral absolute CD4T-cell counts (C),
and neutralization of SHIV-vpu in plasma from animal 95-3 (D). The sensitivity of the RT-PCR assay (A) is indicated by the dotted line (50 copies/ml).
During the first 130 weeks postexposure, no plasma samples were available with an anticoagulant suitable for RT-PCR. In panel C, 500 CD4 T cells/l
are indicated by a dotted line. Anti-Gag antibodies were assessed by enzyme-linked immunodominant assay as described previously (1, 2, 22) and given
as optical density. Homologous neutralization of plasma was tested in triplicate in a modified MT-2 cell assay with SHIV-vpu (D) as described previously
(19). Neutralizing antibody titers are the reciprocal dilution which protected 50% of the MT-2 cells from virus-induced cytotoxicity and correspond to
90% reduction of viral Gag synthesis (6). The lower limit of detection was determined as that giving a titer of 10.
TABLE 1. Outcome of SHIV-vpu or progeny virus infection:
infectious organisms
Monkey Viral inoculum
Time of sacrifice
(weeks after
virus exposure)
Infectious agents
Neonate 95-3 SHIV-vpu 307 Campylobacter coli
Campylobacter jejuni
Pneumocystis carinii
Adult RJj-4 Blood from 95-3
collected at
week 291
43 Giardia lamblia
Campylobacter coli
Adenovirus
Pneumocystis carinii
Adult RMk-4 Blood from RJj-4
collected at
week 2
58 Pneumocystis carinii
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95-3 at week 285 (SHIV-vpu5.285) and at necropsy (SHIV-
vpu5.307) in U87 cells stably expressing various coreceptors
(NIH AIDS Research and Reference Reagent Program). The
progeny viruses productively infected CXCR4- but not CCR5-
expressing cells. However, virus isolated at necropsy also ac-
quired the capacity to replicate in rhesus macaque macro-
phages (data not shown). CXCR4 usage and replication in
macrophages were also found in virus variants isolated from a
laboratory worker who developed AIDS 8 years after acciden-
tal infection with HIV-IIIB (4). Thus, all of these virus variants
had acquired the ability to productively infect macrophages
despite unchanged coreceptor usage.
Sequence analysis of progeny viruses isolated from animal
95-3. Because earlier work had shown that replacing an env
fragment from the acutely pathogenic SHIVKU-1 was sufficient
to convert the nonpathogenic parental SHIV-HXBc2 into a
virus that caused rapid, profound CD4 T-cell loss (termed
SHIV-HXBc2P3.2) (8), we decided to sequence a large gp120-
encoding env segment. We used PCR to clone a 1,226-bp
env fragment from PBMC DNA of monkey 95-3 collected
at different time points. Two clones from week 2 (SHIV-
vpu5.2) and eight clones from week 285 were sequenced
using the following primers: GTAAAACGACGGCCAG, GT
TCAATGGAACAGGACCAT, TTGGAGTACTGAAGGG
TCAA (sense) and CAGGAAACAGCTATGAC, GTGT
CACTTCCTTCAGTGT, ACATTGTACTGTGCTGACAT
(antisense).
We found a higher number of amino acid substitutions and
deletions in SHIV-vpu5.285 env (Fig. 3) than previously re-
ported for rapidly passaged SHIV encoding HXBc2 env or
viruses isolated from the HIV-IIIB-infected laboratory worker
(4, 8, 23, 28, 44, 45). From 10 amino acid substitutions in gp120
linked to the conversion of parental SHIV-HXBc2 into the
acutely pathogenic SHIV-HXBc2P3.2 (8), 5 were identical in
SHIV-vpu5.285 (Table 2, highlighted in bold). Changes were
mainly located in the variable regions of gp120 (Fig. 3). Many
mutations were located in V3, a region that contains linear and
discontinuous antigenic determinants (9, 18, 39) that can
change during disease development and immune escape (37,
38, 41). Some amino acid substitutions led to three new and
loss of two potential N-linked glycosylation sites, which in turn
might result in changes in conformation and immune recogni-
tion of gp120 (3, 12, 14, 29, 30, 35, 47, 50). Two new glycosyl-
ation sites were located in V1 and V2 domains that contain
epitopes for neutralizing antibodies (10, 27, 46) and thus can
modulate neutralization sensitivity (7, 41, 48, 49). There were
two FNTSW sequences in V4 of parental SHIV-vpu; one was
lost by a 5-amino-acid deletion.
HIV-IIIB and SHIV encoding IIIB env undergo similar
gp120 changes during chronic infection in humans or monkeys
or during rapid in vivo passage. Some amino acid changes
leading to alterations in potential glycosylation sites were re-
ported also in viruses isolated after rapid passage or chronic
infection from monkeys or humans (Table 2). Six amino acid
changes found in gp120 of SHIV-vpu5.285 were identical to
those found in gp120 of FF3346 (Table 2), a virus isolated from
the HIV-IIIB-infected laboratory worker (4). These substitu-
tions included a mutation in the highly antigenic sequence,
FIG. 2. Plasma SHIV-vpu RNA load determined by real-time RT-PCR (A), anti-Gag antibodies assessed by enzyme-linked immunodominant
assay (B), peripheral absolute CD4 T-cell counts (C), and virus isolation (D) for recipients RJj-4 and RMk-4. The sensitivity of the RT-PCR assay
(A) is indicated by a dotted line (50 copies/ml). In panel C, 500 and 200 CD4 T cells/l, respectively, are indicated by dotted lines.
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GPGRAF, at the tip of the V3 loop (316A3T). An additional
five changes were located identically in FF3346 and SHIV-
vpu5.285, but the replacing amino acids were different (de-
tails in Table 2).
Summary. We described a general tendency of primate len-
tiviruses to mutate into more virulent forms over time by using
an evolutionary path that was similar within individual hosts of
different species. The virus that evolved in monkey 95-3 over
several years of infection also resembled, to a certain degree,
the viruses selected by rapid serial in vivo passage in pig-tailed
and rhesus macaques. These latter viruses also induced acute
CD4 T-cell depletion and AIDS in infected animals. In all
FIG. 3. Comparison of the gp120 sequence of the parental virus, SHIV-vpu, and the predicted gp120 amino acid sequences of SHIV-vpu5.2
isolated from monkey 95-3 at week 2 directly from PBMC and of SHIV-vpu5.285-1 to SHIV-vpu5.285-8 isolated from 95-3 285 weeks postexposure.
Direct sequencing was not efficient from PBMC collected at week 285; thus, SHIV-vpu5.285 was amplified beforehand for 6 days in CEMx174/GFP
cells. Differences in amino acid residues are indicated, as are the locations of the different regions of gp120 (4). The predicted gp120 amino acid sequence
of two clones isolated at week 2 (SHIV-vpu5.2) was identical to that of the parental virus. The eight clones from week 285 had 39 consistent changes
in gp120 when compared with the sequence of the parental virus: 6 in V1, 7 in V2, 9 in V3, 1 in V4, 3 in V5, and the other 13 in various constant regions.
New potential N-linked glycosylation sites are double underlined; loss of potential N-linked glycosylation sites are single underlined. The gp120 sequence
of SHIV-vpu is identical to that of SHIV-4; the GenBank accession number of the latter is AF038399 (20).
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three species (M. mulatta, M. nemestrina, and Homo sapiens),
progeny viruses became more neutralization resistant (4, 8, 28,
41) and acquired the ability to replicate in macrophages while
maintaining CXCR4-restricted coreceptor usage (4, 23, 44).
Thus, infection with nonpassaged SHIV-vpu in an individual
macaque (i) seems to approximate the evolution of HIV-IIIB
seen during the course of disease progression in a human
individual and (ii) is mirrored by the more rapid evolution that
the virus undergoes during rapid serial passages in nonhuman
primates.
Our results support the use of SHIV-vpu infection of rhe-
sus monkeys as a relevant model that can yield important
insights into viral evolution and pathogenesis. Furthermore,
since rapid viral passage is less time-consuming than long-term
follow-up over years, it seems justifiable to use the former for
safety testing of candidate live attenuated virus vaccines to
uncover potential virulence.
Nucleotide sequence accession numbers. The nucleotide se-
quences of the viral variants isolated 285 weeks after virus
inoculation from diseased monkey 95-3 (Fig. 3) are available
from GenBank (no. AF384152 through AF384159).
We thank T. Graf (Informatics Core, Dana-Farber Cancer Institute)
for support with sequence analyses and C. Gallegos and S. Sharp for
help in preparing the manuscript.
This work was supported in part by NIH grants RO1 AI34266,
RR14180, and DE12937 awarded to R.M.R., AI85343 awarded to
TABLE 2. Similar molecular evolution of HIV-IIIB env sequences in M. mulatta, M. nemestrina, and H. sapiens
SHIV-vpu5.285
amino acid changesa
(M. mulatta)
Region Site
SHIVs containing identical changes HIV-IIIB variant with
identical and/or similar
changes (H. sapiens)M. mulatta M. nemestrina
130 K3N V1 New PGSb SHIV-HXBc2P3.2c (8), SHIVKU-1b
e (28), SHIVKU-PW1, SHIVKU-8124,
SHIVKU-2MC4
c (23), SHIVKU-PEy
f (42), SHIVKU-1 Pnb
f (44),
SHIVKU-2
d (23, 31) SHIVKU-1/105w52, SHIVKU-1/105w98
g (45)
145 G3R V1 SHIVKU-1 Pnb1
146 R3G V1 SHIVKU-1b, SHIVKU-8124, SHIVKU-PW1, FF3346
h (4)
SHIVKU-1/105w98
148 I3M V1 SHIVKU-1/105w52
151 K3E V1 SHIVKU-8124, SHIVKU-1/105w98
161 I3V V2 SHIVKU-1/105w52
166 R3G V2 FF3346 (R3K)h
171 K3R V2 FF3346 (K3E)
175 F3L V2 SHIVKU-1b, SHIVKU-PW1, SHIVKU-PEy
187 D3N V2 New PGS
192 K3T V2 SHIV-HXBc2P3.2, SHIVKU-1b, SHIVKU-PW1, SHIVKU-8124, FF3346
SHIVKU-2MC4 SHIVKU-PEy, SHIVKU-1 Pnb,
SHIVKU-1/105w52, SHIVKU-1/105w98
270 V3I C2 SHIVKU-1 Pnb5
278 T3M C2 Loss of PGS SHIV-HXBc2P3.2, SHIVKU-1b, SHIVKU-8124, SHIVKU-1/105w52,
SHIVKU-2MC4,
SHIVKU-2
SHIVKU-1/105w98, SHIVKU-1 Pnb310
281 A3T C2 CD4 binding SHIVKU-PW1 FF3346 (A3V)
302 N3S V3 New PGS
310 Q3H V3 SHIVKU-1b FF3346
316 A3T V3 GPGRAF FF3346
320 I3M V3 SHIV-HXBc2P3.2, SHIVKU-1b, SHIVKU-PW1, SHIVKU-8124,
SHIVKU-2MC4, SHIVKU-PEy, SHIVKU-1 Pnb,
SHIVKU-2 SHIVKU-1/105w52, SHIVKU-1/105w98
325 N3D V3 SHIV-HXBc2P3.2, SHIVKU-PW1, SHIVKU-8124, SHIVKU-PEy,
SHIVKU-2 SHIVKU-1 Pnb, SHIVKU-1/105w52,
SHIVKU-1/105w98
328 Q3R V3 SHIVKU-1/105w52, SHIVKU-1/105w98
345 I3V C3 FF3346
362 K3E C3 FF3346 (K3R)
396–400
FNSTW
V4 Loss of PGS SHIVKU-PW1, SHIVKU-1 Pnb310
429 K3Q C4 CD4 binding FF3346 (K3E)
464 E3G V5 FF3346
467 I3T V5 SHIVKU-PEy
474 D3N V5 SHIVKU-PEy, SHIVKU-PW1
476 R3K V5 SHIVKU-PEy, SHIVKU-PW1
496 V3I C5 SHIVKU-1b
a Comparison with SHIV-4, AF038399 (20). Changes are listed that concerned potential glycosylation sites or had been reported in other viruses also. Bold type
indicates 5 of 10 amino acid substitutions in SHIV-HXBc2P3.2 gp120 that were reported to be sufficient to confer disease (8).
b PGS, potential glycosylation site.
c Molecular clones acutely pathogenic in rhesus macaques (8, 23).
d Virus stock pathogenic in rhesus macaques (23, 31).
e Neutralization escape variant isolated from a pig-tailed macaque (28).
f Viruses isolated from pig-tailed macaques (42, 44).
g Immune escape virus isolated from a macaque (45).
h Virus isolated from a laboratory worker 7 years after accidental HIV-1 IIIB infection (4). For FF3346, changes are given that are located identically but with
different replacing amino acids.
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